Again with the MSB MSB MSB …. this is CYP …. it appears that it...

First 32 Last

Share
Profile

Follow
col69

15,263 Posts.

5447

08/02/24

18:58

Post #: 72311089
Share

Originally posted by bedger ↑

Because there was running war of words between yourself and others on MSB and Hector that ruined the discourse (and information discovery) on both MSB and CYP threads. All are better off without that.

Lose the aggression with calling me "delusional" etc. if you want a decent conversation. I never said you couldn't comment, I asked you to give it a break - this a thread on coming initial DFU results and you are posting FUD on a CR. You weirdly made no such mention of the keeping the "lights on" on the Appendix 4C only days ago as a claimed holder or capital raise fear-monger. And please excuse me if after years of witnessing trolls, clear shorters and manipulators if I put little trust in anyone's disclosures. And no Col69, I don't intently follow your posts to know where you bought the stock, or give a damn frankly on what could be a 100 lots, or in reality a short, for all I know.

You can indeed comment how you like - within HC guidelines and decent social decorum - and I can similarly respond accordingly....so some actual decent figures on its cash rather than the baseless FUD you posted above.

CYP reports 12.6 qtrs of funding from its formal Appendix 4C - of course not as simple as that - closing the quarter with A$11.2m in cash and operating cash outflows, with the DFU trial in full flow, below $900K. The company itself has guided to at least 2025-26 FY in clearly stated allowance of GvHD trial costs. You might have noticed the DFU trial shortly coming to conclusion? Less R&D expenditure going forward?. LUMFC funding? Sculptor funding/full recruitment? No? You are all about GvHD, which the company has guided for ending enrolment in 2024CY - did you even read the reports? Its only a 60 patient trial with multiple sites and 6 already open for enrolment (3 USA / 3 Australia).

Excuse me if I and others listen to CYP's management's informed financial analysis with their knowledge of their trial expenses on 'having the lights on until at least late 2025' even if no new financing, partnerships or other revenues emerge, rather than your baseless, unevidenced claims otherwise.

By all means give us your analysis to back up your statement that I am, like others including the company CFO, am "delusional if you think CYP have enough funds to run the USA GVHD trial and keep the lights on at the same time". Given you are the one who started making rubbish unfounded statements about it imminently running out of money....in a discussion on coming DFU trial results! How about you back up your clearly unevidenced and misleading statements with a little cited analysis...in the appropriate thread? Probably in your interest as a "shareholder", as you are clearly utterly ill-informed on its likely forward cash burn and continued balance sheet health.

Expand

Again with the MSB MSB MSB …. this is CYP …. it appears that it is you that can’t let things go ?

A USA FDA trial has now expanded globally but hey keep believing that won’t increase the initial estimates / costs ? I am not the only one on on here that has made reference to the costs of the USA FDA GVHD trial and the bank balance - without the exercising of the options I say the company will need a CR … you claim it won’t …. I say good luck with that … @Pledge and others on here have shared my opinion ….. some of us will be right and some will be wrong but regardless I plan to take half off the table here on the back of (hopefully) positive DFU results and let the remainder of my investment (free carry) ride whatever happens awaiting the outcome of the phase 3 osteoarthritis trial …. Enjoy your evening

CYP Price at posting: 18.0¢ Sentiment: Hold Disclosure: Held
2 Upvote

1 Great analysis

Reply